The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

Vyxeos Injection Improves Overall Survival in Phase III Acute Myeloid Leukemia Trial 

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

A phase III trial of Vyxeos Liposome for Injection demonstrated statistically significant improvements in overall survival in patients with high-risk secondary acute myeloid leukemia.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

In Brief

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

John P. Leonard, an expert in lymphoma and other blood cancers, was named director of the Center for Blood Cancers and chief of the Division of Hematology and Medical Oncology in NYU Grossman School of Medicine’s Department of Medicine. The Division of Hematology and Medical Oncology is a major clinical arm of the Perlmutter Cancer Center.
Clinical Roundup

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account